Exane BNP Paribas's Rating Change Only Had Short-term Impact, GlaxoSmithKline Up 1.3% (GSK)
September 21, 2016 at 01:01 AM EDT
Exane BNP Paribas downgraded GlaxoSmithKline (NYSE:GSK) from Neutral to Underperform a week ago. The stock closed at $43.06, which is 1.3% higher than the price one week ago ($42.51).GlaxoSmithKline...